← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

RxSight, Inc. (RXST) 10-Year Financial Performance & Capital Metrics

RXST • • Industrial / General
HealthcareMedical DevicesSurgical & Minimally Invasive DevicesOphthalmic Surgical Devices
AboutRxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Show more
  • Revenue $140M +57.1%
  • EBITDA -$33M +27.5%
  • Net Income -$27M +43.5%
  • EPS (Diluted) -0.71 +49.6%
  • Gross Margin 70.71% +17.2%
  • EBITDA Margin -23.75% +53.8%
  • Operating Margin -26.34% +53.2%
  • Net Margin -19.62% +64.0%
  • ROE -12.43% +68.0%
  • ROIC -12.84% +52.7%
  • Debt/Equity 0.04 +132.8%
  • Interest Coverage -1755.14 -11492.3%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 128.6%
  • ✓Trading at only 1.4x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 12.8% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y128.61%
3Y83.64%
TTM2.67%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-16.41%

EPS CAGR

10Y-
5Y-
3Y-
TTM-6.02%

ROCE

10Y Avg-35.29%
5Y Avg-33.31%
3Y Avg-30.16%
Latest-16.23%

Peer Comparison

Ophthalmic Surgical Devices
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SGHTSight Sciences, Inc.348.95M6.60-6.41-1.47%-60.63%-71.72%0.46
RXSTRxSight, Inc.402.53M9.79-13.7957.09%-25.15%-12.95%0.04

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+2.24M14.68M22.59M49.01M89.08M139.93M
Revenue Growth %-5.55%0.54%1.17%0.82%0.57%
Cost of Goods Sold+4.06M12.97M18.08M27.68M35.31M40.98M
COGS % of Revenue1.81%0.88%0.8%0.56%0.4%0.29%
Gross Profit+-1.82M1.71M4.52M21.33M53.77M98.94M
Gross Margin %-0.81%0.12%0.2%0.44%0.6%0.71%
Gross Profit Growth %-1.94%1.65%3.72%1.52%0.84%
Operating Expenses+44.25M37.11M57.3M84.65M103.85M135.8M
OpEx % of Revenue19.75%2.53%2.54%1.73%1.17%0.97%
Selling, General & Admin15.2M15.18M32.8M58.66M74.8M101.43M
SG&A % of Revenue6.78%1.03%1.45%1.2%0.84%0.72%
Research & Development29.57M21.93M24.5M25.98M29.05M34.37M
R&D % of Revenue13.19%1.49%1.08%0.53%0.33%0.25%
Other Operating Expenses-521K00000
Operating Income+-46.07M-35.41M-52.79M-63.32M-50.09M-36.86M
Operating Margin %-20.56%-2.41%-2.34%-1.29%-0.56%-0.26%
Operating Income Growth %-0.23%-0.49%-0.2%0.21%0.26%
EBITDA+-42.14M-31.39M-48.8M-59.3M-45.84M-33.23M
EBITDA Margin %-18.8%-2.14%-2.16%-1.21%-0.51%-0.24%
EBITDA Growth %-0.26%-0.55%-0.22%0.23%0.28%
D&A (Non-Cash Add-back)3.93M4.01M3.99M4.02M4.24M3.62M
EBIT126.27M28.14M-45M-61.8M-45.28M-27.38M
Net Interest Income+2.28M33K-3.63M-3.43M3.27M9.45M
Interest Income2.31M543K54K1.52M6.57M9.47M
Interest Expense26K510K3.68M4.95M3.31M21K
Other Income/Expense172.31M63.04M4.11M-3.43M1.5M9.45M
Pretax Income+126.24M27.63M-48.68M-66.75M-48.59M-27.41M
Pretax Margin %56.33%1.88%-2.15%-1.36%-0.55%-0.2%
Income Tax+24K57K8K9K20K50K
Effective Tax Rate %1%1%1%1%1%1%
Net Income+126.22M27.57M-48.69M-66.76M-48.61M-27.45M
Net Margin %56.32%1.88%-2.16%-1.36%-0.55%-0.2%
Net Income Growth %--0.78%-2.77%-0.37%0.27%0.44%
Net Income (Continuing)126.22M27.57M-48.69M-66.76M-48.61M-27.45M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+6.620.18-1.78-2.41-1.41-0.71
EPS Growth %--0.97%-10.89%-0.35%0.41%0.5%
EPS (Basic)0.950.18-1.78-2.41-1.41-0.71
Diluted Shares Outstanding19.07M19.07M27.37M27.66M34.46M38.87M
Basic Shares Outstanding19.07M19.07M27.37M27.66M34.46M38.87M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+90.2M81.5M176.29M134.56M168.41M293.82M
Cash & Short-Term Investments80.67M68.97M159.33M105.8M127.18M237.22M
Cash Only7.96M13.99M24.36M11.83M9.69M16.71M
Short-Term Investments72.71M54.98M134.97M93.97M117.49M220.52M
Accounts Receivable789K2.87M4.86M10.96M20.28M30.05M
Days Sales Outstanding128.5171.2478.5581.683.178.39
Inventory7.22M8.29M8.03M14.84M17.42M22.01M
Days Inventory Outstanding649233.19162.19195.64180.07196.01
Other Current Assets0002.96M3.52M4.54M
Total Non-Current Assets+20.23M19.18M16.43M15.61M14.14M24.74M
Property, Plant & Equipment19.25M18.61M15.5M14.08M13.29M23.63M
Fixed Asset Turnover0.12x0.79x1.46x3.48x6.71x5.92x
Goodwill000000
Intangible Assets000000
Long-Term Investments0000711K750K
Other Non-Current Assets983K571K925K1.53M147K360K
Total Assets+110.43M100.68M192.72M150.16M182.55M318.56M
Asset Turnover0.02x0.15x0.12x0.33x0.49x0.44x
Asset Growth %--0.09%0.91%-0.22%0.22%0.75%
Total Current Liabilities+8.46M11.6M11.08M17.24M20.9M25.88M
Accounts Payable2.2M1.13M1.69M2.6M3.86M4.54M
Days Payables Outstanding197.6931.9134.1134.2239.9340.47
Short-Term Debt000000
Deferred Revenue (Current)378K417K618K1000K1000K1000K
Other Current Liabilities4.89M8.78M6.92M10.87M2.56M17.25M
Current Ratio10.67x7.03x15.92x7.81x8.06x11.36x
Quick Ratio9.81x6.31x15.19x6.95x7.22x10.50x
Cash Conversion Cycle579.81272.52206.63243.02223.24233.93
Total Non-Current Liabilities+406.59M386.61M43.4M43.02M1.28M11.45M
Long-Term Debt024.4M39.76M40.17M00
Capital Lease Obligations4.53M5.08M3.64M2.86M1.21M11.32M
Deferred Tax Liabilities000000
Other Non-Current Liabilities402.06M357.13M0074K127K
Total Liabilities415.04M398.21M54.48M60.26M22.19M37.33M
Total Debt+5.52M30.75M44.93M44.99M3.01M12.3M
Net Debt-2.44M16.76M20.57M33.16M-6.68M-4.41M
Debt / Equity--0.33x0.50x0.02x0.04x
Debt / EBITDA------
Net Debt / EBITDA------
Interest Coverage-1771.92x-69.42x-14.34x-12.80x-15.14x-1755.14x
Total Equity+-304.61M-297.53M138.24M89.9M160.36M281.24M
Equity Growth %-0.02%1.46%-0.35%0.78%0.75%
Book Value per Share-15.97-15.605.053.254.657.24
Total Shareholders' Equity-304.61M-297.53M138.24M89.9M160.36M281.24M
Common Stock56.42M80.78M27K28K36K40K
Retained Earnings-419.86M-430.59M-479.28M-546.03M-594.64M-622.1M
Treasury Stock000000
Accumulated OCI46K-3K-20K-95K-5K166K
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-40.62M-35.2M-44.71M-58.85M-41.59M-16.95M
Operating CF Margin %-18.13%-2.4%-1.98%-1.2%-0.47%-0.12%
Operating CF Growth %-0.13%-0.27%-0.32%0.29%0.59%
Net Income126.22M27.57M-48.69M-66.76M-48.61M-27.45M
Depreciation & Amortization3.93M4.01M3.99M4.02M4.24M3.62M
Stock-Based Compensation4.6M4.18M7.58M11.4M15.75M24.64M
Deferred Taxes0-63.21M-5.4M000
Other Non-Cash Items-171.4M85K493K-101K-3.9M-8.54M
Working Capital Changes-3.97M-7.85M-2.68M-7.41M-9.07M-9.21M
Change in Receivables-789K-2.08M-2M-6.09M-9.32M-9.8M
Change in Inventory-5.47M-1.31M-2.11M-7.55M-2.75M-4.99M
Change in Payables1.13M-954K555K635K1.25M946K
Cash from Investing+-5.87M15.59M-81.91M39.95M-22.13M-99.31M
Capital Expenditures-4.09M-2.54M-1.94M-2.39M-4.81M-5.44M
CapEx % of Revenue1.82%0.17%0.09%0.05%0.05%0.04%
Acquisitions------
Investments------
Other Investing00-79.97M42.34M-17.32M0
Cash from Financing+1.33M25.24M137.34M6.33M61.52M123.32M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing1.51M-636K1.23M-1.38M-4.28M-5.54M
Net Change in Cash------
Free Cash Flow+-44.7M-37.74M-46.65M-61.24M-46.41M-22.39M
FCF Margin %-19.95%-2.57%-2.06%-1.25%-0.52%-0.16%
FCF Growth %-0.16%-0.24%-0.31%0.24%0.52%
FCF per Share-2.34-1.98-1.70-2.21-1.35-0.58
FCF Conversion (FCF/Net Income)-0.32x-1.28x0.92x0.88x0.86x0.62x
Interest Paid26K425K3.19M4.26M3.48M21K
Taxes Paid19K61K20K3K8K24K

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)---35.22%-58.52%-38.85%-12.43%
Return on Invested Capital (ROIC)---24.93%-33.69%-27.15%-12.84%
Gross Margin-81.17%11.62%19.99%43.52%60.36%70.71%
Net Margin5632.31%187.87%-215.5%-136.22%-54.57%-19.62%
Debt / Equity--0.33x0.50x0.02x0.04x
Interest Coverage-1771.92x-69.42x-14.34x-12.80x-15.14x-1755.14x
FCF Conversion-0.32x-1.28x0.92x0.88x0.86x0.62x
Revenue Growth-554.98%53.92%116.9%81.77%57.09%

Revenue by Segment

20212024
RxLAL-96.5M
RxLAL Growth--
L D D13.77M39.7M
L D D Growth-188.25%
Service Warranty Service Contracts And Accessories656K3.73M
Service Warranty Service Contracts And Accessories Growth-467.99%
L A L8.16M-
L A L Growth--

Frequently Asked Questions

Growth & Financials

RxSight, Inc. (RXST) reported $142.1M in revenue for fiscal year 2024. This represents a 6240% increase from $2.2M in 2019.

RxSight, Inc. (RXST) grew revenue by 57.1% over the past year. This is strong growth.

RxSight, Inc. (RXST) reported a net loss of $35.7M for fiscal year 2024.

Dividend & Returns

RxSight, Inc. (RXST) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.

RxSight, Inc. (RXST) had negative free cash flow of $22.2M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.